Session 1, 8:15 AM
Trends in Oncology Care

• Moderator: Barry Fortner, ION Solutions
  – Escalating Drug Prices
    • Kalipso Chalkidou, NICE International (via webex)
  – Consolidation of practices in hospital partnerships/changing of oncology practice
    • Bruce Gould, Community Oncology Alliance
  – The Financial Toxicity of Cancer Treatment: Can Patients Cope with Costs?
    • Yousuf Zafar, Duke University Medical School, Duke Cancer Center
  – Drug Shortages
    • Peyton Howell, Amerisource Bergen
  – CMS reimbursement policies in oncology
    • Marc Hartstein, Center for Medicare & Medicaid Services
Keynote Address, 11:00 AM

• Pharma pricing practices and the case for market self correction
  – Alex Bastian, GfK Custom Research, LLC
Session 2, 12:15 PM
Paradoxes of Cancer Drug Reimbursement

• Moderator: Jeffrey Ward, Swedish Cancer Institute
  – Brand name drugs v. generics
    • Jeffrey Peppercorn, Duke University Medical School
  – Oral vs. IV drugs
    • Lee Newcomer, United Health Group
  – 340b vs. everyone else
    • Rena Conti, University of Chicago
  – Private Practice v. hospital-based care
    • Eric Hammelman, Avalere Health
  – Variable co-insurance and premiums
    • Michael Kolodziej, Aetna
Session 3, 3:00 PM
Value and Policy Options

• Moderator: Scott Ramsey, Fred Hutchinson Cancer Center
  – The Patient Perspective
    • Shelley Fuld Nasso, National Coalition for Cancer Survivorship
  – Value based insurance design
    • Mark Fendrick, University of Michigan Center for Value Based Insurance Design
  – Bundling of Payments
    • Thomas Feeley, MD Anderson Cancer Center
  – Value-based drug pricing
    • Patricia Danzon, The Wharton School, University of Pennsylvania
  – Lessons from the Health Evidence Review Commission, Oregon Health Authority
    • Kevin Olson, Providence Cancer Center
No more chemo. Docs say it's not so far off.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

**Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia**

*Stacie B. Dusetzina, Aaron N. Winn, Gregory A. Abel, Haiden A. Huskamp, and Nancy L. Keating*

November 8, 2012

Sanofi Halves Price of Cancer Drug Zaltrap After Sloan-Kettering Rejection

By ANDREW POLLACK

Washington

For Bankruptcy Than People Without A Cancer Diagnosis
Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval
1965 - 2014

Source: Peter B. Bach, MD, Memorial Sloan-Kettering Cancer Center
Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval

1965 - 2014

Source: Peter B. Bach, MD, Memorial Sloan-Kettering Cancer Center
## A Tale of Two Drugs

<table>
<thead>
<tr>
<th></th>
<th>Xalkori</th>
<th>Zykadia</th>
<th>Drug A</th>
<th>Drug B</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ORR</strong></td>
<td>50% (42%, 59%)</td>
<td>54.6% (47, 62)</td>
<td>61% (52%, 70%)</td>
<td>43.6% (36, 52)</td>
</tr>
<tr>
<td><strong>Duration of response (months)</strong></td>
<td>9.7 (1.4+, 9.7+)</td>
<td>7.4 (5.4, 10.1)</td>
<td>11.1 (0.9+, 17.7+)</td>
<td>7.1 (5.6, NE)</td>
</tr>
<tr>
<td><strong>Reasonable side effect profile</strong></td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td><strong>Frequency</strong></td>
<td>twice per day</td>
<td>once per day</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Approval required RCT</strong></td>
<td>NO</td>
<td>NO</td>
<td>YES</td>
<td>NO</td>
</tr>
<tr>
<td><strong>Number of approval trials</strong></td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total sample size</strong></td>
<td>255</td>
<td>163</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>First in class</strong></td>
<td>NO</td>
<td>YES</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Companion diagnostic codeveloped</strong></td>
<td>YES</td>
<td>NO</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Which should cost more?</strong></td>
<td>✔</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cost ($2013, at approval)</strong></td>
<td>$11,375</td>
<td>$13,276</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Thank You